Mustargen, Ledaga(mechlorethamine)
Ledaga, Valchlor (mechlorethamine) is a small molecule pharmaceutical. Mechlorethamine was first approved as Mustargen on 1982-01-01. It is used to treat hodgkin disease, malignant pleural effusion, mycosis fungoides, and neoplasm metastasis in the USA. It has been approved in Europe to treat mycosis fungoides.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Valchlor (discontinued: Mustargen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mechlorethamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VALCHLOR | Helsinn Birex Pharmaceuticals | N-202317 RX | 2013-08-23 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hodgkin disease | — | D006689 | C81 |
| malignant pleural effusion | — | D016066 | J91.0 |
| mycosis fungoides | — | D009182 | C84.0 |
| neoplasm metastasis | EFO_0009708 | D009362 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg |
Clinical
Clinical Trials
307 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 15 | 22 | — | 1 | 4 | 33 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 11 | 8 | 2 | 1 | 3 | 22 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 5 | 6 | — | 1 | — | 11 |
| Burkitt lymphoma | D002051 | — | C83.7 | 2 | 2 | — | 1 | 3 | 7 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | 2 | — | 1 | 1 | 5 |
| Transposition of great vessels | D014188 | — | Q20.3 | — | — | — | 1 | 1 | 2 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | — | — | — | 1 | 1 | — | 2 |
| Arterial switch operation | D000069278 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 17 | 30 | 4 | — | 2 | 44 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 10 | 12 | 4 | — | 3 | 27 |
| Sarcoma | D012509 | — | — | 6 | 10 | 5 | — | 4 | 22 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 9 | 11 | 2 | — | 2 | 22 |
| Myelodysplastic syndromes | D009190 | — | D46 | 8 | 12 | 1 | — | 1 | 20 |
| Lymphoma | D008223 | — | C85.9 | 4 | 12 | 5 | — | — | 20 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 6 | 4 | 3 | — | 1 | 14 |
| Neoplasms | D009369 | — | C80 | 9 | 1 | 1 | — | 1 | 11 |
| Osteosarcoma | D012516 | — | — | 4 | 4 | 2 | — | 2 | 9 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 4 | — | 2 | — | 1 | 7 |
Show 28 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | — | C81 | 11 | 17 | — | — | 3 | 25 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 7 | 8 | — | — | 3 | 14 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 6 | — | — | 3 | 12 |
| Follicular lymphoma | D008224 | — | C82 | 3 | 6 | — | — | 4 | 10 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 8 | — | — | 1 | 9 |
| Primary myelofibrosis | D055728 | — | D47.4 | 3 | 5 | — | — | 1 | 9 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 2 | 5 | — | — | 1 | 8 |
| Mycosis fungoides | D009182 | — | C84.0 | 1 | 5 | — | — | 2 | 8 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 2 | 3 | — | — | 4 | 8 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | 6 | — | — | 1 | 7 |
Show 84 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wilms tumor | D009396 | EFO_0000212 | — | 3 | — | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | 1 | 2 |
| Ependymoma | D004806 | — | — | 2 | — | — | — | — | 2 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 2 | — | — | — | — | 2 |
| Rhabdoid tumor | D018335 | — | — | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Choroid plexus neoplasms | D016545 | EFO_0007206 | — | 1 | — | — | — | — | 1 |
| Phenylketonurias | D010661 | — | E70.0 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 3 | 3 |
| Intraocular lymphoma | D064090 | — | — | — | — | — | — | 2 | 2 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 1 | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | — | — | 1 | 1 |
| Chikungunya fever | D065632 | — | A92.0 | — | — | — | — | 1 | 1 |
| Molecular imaging | D057054 | — | — | — | — | — | — | 1 | 1 |
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mechlorethamine |
| INN | chlormethine |
| Description | Mechlorethamine is a nitrogen mustard and an organochlorine compound. It has a role as an alkylating agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(CCCl)CCCl |
Identifiers
| PDB | — |
| CAS-ID | 51-75-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL427 |
| ChEBI ID | 28925 |
| PubChem CID | 4033 |
| DrugBank | DB00888 |
| UNII ID | 50D9XSG0VR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,022 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,514 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use